⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 18, 2025Melanoma ManagementOpen Access

Patient preferences for stages II–IV melanoma treatments in the UK: results from a cross-sectional study

Luis Vaz S. Vekeria Amal Sadou Alissar Moussallem Alba López Noval Xavier Guillaume Gemma S. Cairns

View Full Paper

Ask AI

Bookmark

Share

Key Points

Patients expressed distinct preferences for treatment attributes in managing melanoma, affecting care strategies.
The study analyzed preferences related to adjuvant and metastatic melanoma treatments among participants in the UK.
Data were gathered through a cross-sectional approach examining various treatment attributes patients prioritize.
These results may enable tailored treatment decisions based on patient-centered preferences for melanoma care.

Implication

Cross-sectional study reveals treatment attribute preferences for melanoma, indicating how they may affect care decisions.

Abstract

Aim To understand patient preferences for treatment attributes in adjuvant and metastatic melanoma in the UK.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vaz et al. (2025) studied this question.

synapsesocial.com/papers/68f64fbb2509bc8625bfb225 https://doi.org/10.1080/20450885.2025.2570112

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry2024
2Preferences of Dermato-oncologists for Adjuvant Therapy in Stage II Melanoma: A Nationwide Discrete Choice Experiment2025
3DS26 Identifying patient research priorities in melanoma: a national qualitative study2024
4Meaningful efficacy measures and trial endpoints in patients with advanced melanoma being considered for adjuvant systemic therapy: a prospective patient survey studyHuman Clinical Trial · 2026
5Refining adjuvant therapy options in patients with stage II melanomaOriginal Research · 2026

Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ32026
5-year overall survival after adjuvant treatment for stage III melanoma: An English nationwide registry-based study.2026
Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US2024
Insurance, race, and socioeconomic disparities in systemic therapy receipt for melanoma in the United States: a systematic reviewMelanoma Management · 2026
Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case seriesMelanoma Management · 2025

More from Melanoma Management

More from Bristol-Myers Squibb (United Kingdom)

More from Oracle (United Kingdom)